Sara E Swift

US Patent:

20210047323, Feb 18, 2021

Filed:

Aug 13, 2020

Appl. No.:

16/992441

Inventors:

- Boston MA, US
Kevin J. Gagnon - Acton MA, US
Jicong Li - Cambridge MA, US
Jennifer Lu - San Diego CA, US
Ales Medek - Winchester MA, US
Muna Shrestha - Belmont MA, US
Michael Waldo - Grafton MA, US
Beili Zhang - San Diego CA, US
Carl L. Zwicker - Wakefield MA, US
Corey Don Anderson - Brighton MA, US
Jeremy J. Clemens - San Diego CA, US
Thomas Cleveland - San Marcos CA, US
Timothy Richard Coon - Carlsbad CA, US
Bryan Frieman - La Jolla CA, US
Peter Grootenhuis - Del Mar CA, US
Sara Sabina Hadida Ruah - La Jolla CA, US
Jason McCartney - Cardiff by the Sea CA, US
Mark Thomas Miller - Rancho Santa Fe CA, US
Prasuna Paraselli - San Diego CA, US
Fabrice Pierre - La Jolla CA, US
Sara E. Swift - San Diego CA, US
Jinglan Zhou - San Diego CA, US

International Classification:

C07D 471/08

Abstract:

Crystalline forms of Compound I:pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

US Patent:

20210047345, Feb 18, 2021

Filed:

Aug 13, 2020

Appl. No.:

16/992419

Inventors:

- Boston MA, US
John E. Cochran - Marshfield MA, US
Benjamin J. Littler - Carlsbad CA, US
David Siesel - San Diego CA, US
Armando Urbina - San Diego CA, US
Corey Don Anderson - Brighton MA, US
Jeremy J. Clemens - San Diego CA, US
Thomas Cleveland - San Marcos CA, US
Timothy Richard Coon - Carlsbad CA, US
Bryan Frieman - La Jolla CA, US
Peter Grootenhuis - Del Mar CA, US
Sara Sabina Hadida Ruah - La Jolla CA, US
Jason McCartney - Cardiff by the Sea CA, US
Mark Thomas Miller - San Diego CA, US
Prasuna Paraselli - San Diego CA, US
Fabrice Pierre - La Jolla CA, US
Sara E. Swift - San Diego CA, US
Jinglan Zhou - San Diego CA, US

International Classification:

C07D 513/22
C07D 401/14
C07D 401/04
C07D 213/71
C07D 213/82
C07D 207/08
C07D 231/20

Abstract:

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

US Patent:

20210047350, Feb 18, 2021

Filed:

Aug 13, 2020

Appl. No.:

16/992448

Inventors:

- Boston MA, US
Jeremy J. Clemens - San Diego CA, US
Thomas Cleveland - San Marcos CA, US
Timothy Richard Coon - Carlsbad CA, US
Bryan Frieman - La Jolla CA, US
Peter Grootenhuis - Del Mar CA, US
Sara Sabina Hadida Ruah - La Jolla CA, US
Jason McCartney - Cardiff by the Sea CA, US
Mark Thomas Miller - San Diego CA, US
Prasuna Paraselli - San Diego CA, US
Fabrice Pierre - La Jolla CA, US
Sara E. Swift - San Diego CA, US
Jinglan Zhou - San Diego CA, US

International Classification:

C07F 7/08
C07F 7/30
A61K 31/404
A61K 31/47

Abstract:

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

US Patent:

20190248809, Aug 15, 2019

Filed:

Feb 14, 2019

Appl. No.:

16/276350

Inventors:

- Boston MA, US
Alexander Russell Abela - Escondido CA, US
Corey Don Anderson - San Diego CA, US
Brett B. Busch - San Diego CA, US
Weichao George Chen - San Diego CA, US
Thomas Cleveland - San Marcos CA, US
Timothy Richard Coon - Carlsbad CA, US
Bryan Frieman - La Jolla CA, US
Senait G. Ghirmai - San Diego CA, US
Peter Grootenhuis - Del Mar CA, US
Anton V. Gulevich - San Diego CA, US
Sara Sabina Hadida Ruah - La Jolla CA, US
Clara Kuang-Ju Hsia - San Diego CA, US
Ping Kang - San Diego CA, US
Haripada Khatuya - San Diego CA, US
Jason McCartney - Cardiff by the Sea CA, US
Mark Thomas Miller - San Diego CA, US
Prasuna Paraselli - San Diego CA, US
Fabrice Pierre - La Jolla CA, US
Sara E. Swift - San Diego CA, US
Andreas Termin - Encinitas CA, US
Johnny Uy - San Diego CA, US
Carl V. Vogel - Carlsbad CA, US
Jinglan Zhou - San Diego CA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Boston MA

International Classification:

C07D 513/22
A61K 31/439
A61K 31/404
A61K 31/47
A61P 11/00

Abstract:

Compounds of Formula (I):pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.